Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.

Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS Investigators.

Gastroenterology. 2019 Sep;157(3):682-691.e2. doi: 10.1053/j.gastro.2019.05.056. Epub 2019 May 29.

PMID:
31152740
2.

Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients.

Khunti K, Jung H, Dans AL, Held C, Dagenais GR, Yusuf S, Lonn E.

Can J Cardiol. 2019 May;35(5):644-652. doi: 10.1016/j.cjca.2019.03.002. Epub 2019 Mar 19.

PMID:
31030865
3.

Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries.

Wang C, Bangdiwala SI, Rangarajan S, Lear SA, AlHabib KF, Mohan V, Teo K, Poirier P, Tse LA, Liu Z, Rosengren A, Kumar R, Lopez-Jaramillo P, Yusoff K, Monsef N, Krishnapillai V, Ismail N, Seron P, Dans AL, Kruger L, Yeates K, Leach L, Yusuf R, Orlandini A, Wolyniec M, Bahonar A, Mohan I, Khatib R, Temizhan A, Li W, Yusuf S.

Eur Heart J. 2019 May 21;40(20):1620-1629. doi: 10.1093/eurheartj/ehy695.

PMID:
30517670
4.

Cause and consequence of loss in vaccine trust.

Dans AL, Dans LF, Silvestre MAA, Halstead SB, Guyatt GH.

Hum Vaccin Immunother. 2019;15(3):628-629. doi: 10.1080/21645515.2018.1551674. Epub 2018 Dec 11. No abstract available.

PMID:
30513242
5.

The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.

Joseph P, Pais P, Dans AL, Bosch J, Xavier D, Lopez-Jaramillo P, Yusoff K, Santoso A, Talukder S, Gamra H, Yeates K, Lopez PC, Tyrwhitt J, Gao P, Teo K, Yusuf S; TIPS-3 Investigators.

Am Heart J. 2018 Dec;206:72-79. doi: 10.1016/j.ahj.2018.07.012. Epub 2018 Aug 2.

6.

Responsive and Equitable Health Systems-Partnership on Non-Communicable Diseases (RESPOND) study: a mixed-methods, longitudinal, observational study on treatment seeking for hypertension in Malaysia and the Philippines.

Palafox B, Seguin ML, McKee M, Dans AL, Yusoff K, Candari CJ, Idris K, Ismail JR, Krauss SE, Lasco G, Majid FA, Palileo-Villanueva LM, Razak AA, Renedo A, Balabanova D.

BMJ Open. 2018 Jul 30;8(7):e024000. doi: 10.1136/bmjopen-2018-024000.

7.

Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study.

Langhorne P, O'Donnell MJ, Chin SL, Zhang H, Xavier D, Avezum A, Mathur N, Turner M, MacLeod MJ, Lopez-Jaramillo P, Damasceno A, Hankey GJ, Dans AL, Elsayed A, Mondo C, Wasay M, Czlonkowska A, Weimar C, Yusufali AH, Hussain FA, Lisheng L, Diener HC, Ryglewicz D, Pogosova N, Iqbal R, Diaz R, Yusoff K, Oguz A, Wang X, Penaherrera E, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Magazi D, Nilanont Y, Rosengren A, Oveisgharan S, Yusuf S; INTERSTROKE collaborators.

Lancet. 2018 May 19;391(10134):2019-2027. doi: 10.1016/S0140-6736(18)30802-X. Epub 2018 May 17.

PMID:
29864018
8.

Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study.

Murphy A, Palafox B, O'Donnell O, Stuckler D, Perel P, AlHabib KF, Avezum A, Bai X, Chifamba J, Chow CK, Corsi DJ, Dagenais GR, Dans AL, Diaz R, Erbakan AN, Ismail N, Iqbal R, Kelishadi R, Khatib R, Lanas F, Lear SA, Li W, Liu J, Lopez-Jaramillo P, Mohan V, Monsef N, Mony PK, Puoane T, Rangarajan S, Rosengren A, Schutte AE, Sintaha M, Teo KK, Wielgosz A, Yeates K, Yin L, Yusoff K, Zatońska K, Yusuf S, McKee M.

Lancet Glob Health. 2018 Mar;6(3):e292-e301. doi: 10.1016/S2214-109X(18)30031-7.

9.

Does greater individual social capital improve the management of hypertension? Cross-national analysis of 61 229 individuals in 21 countries.

Palafox B, Goryakin Y, Stuckler D, Suhrcke M, Balabanova D, Alhabib KF, Avezum A, Bahonar A, Bai X, Chifamba J, Dans AL, Diaz R, Gupta R, Iqbal R, Ismail N, Kaur M, Keskinler MV, Khatib R, Kruger A, Kruger IM, Lanas F, Lear SA, Li W, Liu J, Lopez-Jaramillo P, Peer N, Poirier P, Rahman O, Pillai RK, Rangarajan S, Rosengren A, Swaminathan S, Szuba A, Teo K, Wang Y, Wielgosz A, Yeates KE, Yusufali A, Yusuf S, McKee M.

BMJ Glob Health. 2017 Dec 17;2(4):e000443. doi: 10.1136/bmjgh-2017-000443. eCollection 2017.

10.

Controversy and debate on dengue vaccine series-paper 3: final response to review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs.

Dans AL, Dans LF, Lansang MAD, Silvestre MAA, Guyatt GH.

J Clin Epidemiol. 2018 Mar;95:142. doi: 10.1016/j.jclinepi.2017.12.025. Epub 2018 Jan 3. No abstract available.

PMID:
29306065
11.

Controversy and debate on dengue vaccine series-paper 1: review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs.

Dans AL, Dans LF, Lansang MAD, Silvestre MAA, Guyatt GH.

J Clin Epidemiol. 2018 Mar;95:137-139. doi: 10.1016/j.jclinepi.2017.11.019. Epub 2017 Nov 24. Review.

PMID:
29180056
12.

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, Metsarinne K, O'Donnell M, Dans AL, Ha JW, Parkhomenko AN, Avezum AA, Lonn E, Lisheng L, Torp-Pedersen C, Widimsky P, Maggioni AP, Felix C, Keltai K, Hori M, Yusoff K, Guzik TJ, Bhatt DL, Branch KRH, Cook Bruns N, Berkowitz SD, Anand SS, Varigos JD, Fox KAA, Yusuf S; COMPASS investigators.

Lancet. 2018 Jan 20;391(10117):205-218. doi: 10.1016/S0140-6736(17)32458-3. Epub 2017 Nov 10. Erratum in: Lancet. 2017 Dec 21;:.

PMID:
29132879
13.

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators.

N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.

14.

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.

Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M, Lonn EM, Widimsky P, Hori M, Avezum A, Piegas LS, Bhatt DL, Branch KRH, Probstfield JL, Liang Y, Liu L, Zhu J, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Fox KAA, Kakkar A, Parkhomenko AN, Ertl G, Störk S, Keltai K, Keltai M, Ryden L, Dagenais GR, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Ha JW, Tonkin AM, Varigos JD, Lewis BS, Felix C, Yusoff K, Steg PG, Aboyans V, Metsarinne KP, Anand SS, Hart RG, Lamy A, Moayyedi P, Leong DP, Sharma M, Yusuf S.

Can J Cardiol. 2017 Aug;33(8):1027-1035. doi: 10.1016/j.cjca.2017.06.001. Epub 2017 Jun 8. Review.

15.

Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.

O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, Rao-Melacini P, Zhang X, Pais P, Agapay S, Lopez-Jaramillo P, Damasceno A, Langhorne P, McQueen MJ, Rosengren A, Dehghan M, Hankey GJ, Dans AL, Elsayed A, Avezum A, Mondo C, Diener HC, Ryglewicz D, Czlonkowska A, Pogosova N, Weimar C, Iqbal R, Diaz R, Yusoff K, Yusufali A, Oguz A, Wang X, Penaherrera E, Lanas F, Ogah OS, Ogunniyi A, Iversen HK, Malaga G, Rumboldt Z, Oveisgharan S, Al Hussain F, Magazi D, Nilanont Y, Ferguson J, Pare G, Yusuf S; INTERSTROKE investigators.

Lancet. 2016 Aug 20;388(10046):761-75. doi: 10.1016/S0140-6736(16)30506-2. Epub 2016 Jul 16.

PMID:
27431356
16.

Revering the irreverent.

Dans AL, Dans LF.

J Clin Epidemiol. 2016 May;73:64-6. doi: 10.1016/j.jclinepi.2016.02.013. Epub 2016 Feb 28. No abstract available.

PMID:
26931295
17.

Digitalis for treatment of heart failure in patients in sinus rhythm.

Hood WB Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ.

Cochrane Database Syst Rev. 2014 Apr 28;(4):CD002901. doi: 10.1002/14651858.CD002901.pub3. Review.

PMID:
24771511
18.

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.

Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S.

Circulation. 2013 Jul 16;128(3):237-43. doi: 10.1161/CIRCULATIONAHA.112.001139. Epub 2013 Jun 14.

PMID:
23770747
19.

Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation.

Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, Xavier D, Kim SS, Omar R, Dans AL, Tan RS, Chen JH, Tanomsup S, Watanabe M, Koyanagi M, Ezekowitz MD, Reilly PA, Wallentin L, Yusuf S; RE-LY Investigators.

Stroke. 2013 Jul;44(7):1891-6. doi: 10.1161/STROKEAHA.113.000990. Epub 2013 Jun 6.

PMID:
23743976
20.

Response to Dr Junqueira.

Linkins LA, Dans AL, Moores CLK, Davidson BL, Schulman S, Crowther M.

Chest. 2013 Apr;143(4):1191. doi: 10.1378/chest.13-0035. No abstract available.

PMID:
23546509
21.

Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.

Dans AL, Connolly SJ, Wallentin L, Yang S, Nakamya J, Brueckmann M, Ezekowitz M, Oldgren J, Eikelboom JW, Reilly PA, Yusuf S.

Circulation. 2013 Feb 5;127(5):634-40. doi: 10.1161/CIRCULATIONAHA.112.115386. Epub 2012 Dec 27.

PMID:
23271794
22.

Prevalence of atherosclerosis-related risk factors and diseases in the Philippines.

Sy RG, Morales DD, Dans AL, Paz-Pacheco E, Punzalan FE, Abelardo NS, Duante CA.

J Epidemiol. 2012;22(5):440-7. Epub 2012 Jul 14.

23.

Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.

Verdecchia P, Dagenais G, Healey J, Gao P, Dans AL, Chazova I, Binbrek AS, Iacobellis G, Ferreira R, Holwerda N, Karatzas N, Keltai M, Mancia G, Sleight P, Teo K, Yusuf S; Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint TrialTelmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease Investigators.

J Hypertens. 2012 May;30(5):1004-14. doi: 10.1097/HJH.0b013e3283522a51.

PMID:
22495138
24.

Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M.

Chest. 2012 Feb;141(2 Suppl):e495S-e530S. doi: 10.1378/chest.11-2303. Review. Erratum in: Chest. 2015 Dec;148(6):1529.

25.

Apixaban in patients with atrial fibrillation.

Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim KH, Lewis BS, Van Mieghem W, Lip GY, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O'Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S; AVERROES Steering Committee and Investigators.

N Engl J Med. 2011 Mar 3;364(9):806-17. doi: 10.1056/NEJMoa1007432. Epub 2011 Feb 10.

26.

In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events.

Dans AL, Teo K, Gao P, Chen JH, Jae-Hyung K, Yusoff K, Chaithiraphan S, Zhu J, Lisheng L, Yusuf S; Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial Investigators.

PLoS One. 2010 Dec 21;5(12):e13694. doi: 10.1371/journal.pone.0013694.

27.

Trade-off between benefit and harm is crucial in health screening recommendations. Part I: general principles.

Dans LF, Silvestre MA, Dans AL.

J Clin Epidemiol. 2011 Mar;64(3):231-9. doi: 10.1016/j.jclinepi.2010.09.009. Epub 2010 Dec 30.

PMID:
21194890
28.

Trade-off between benefit and harm is crucial in health screening recommendations. Part II: evidence summaries.

Silvestre MA, Dans LF, Dans AL.

J Clin Epidemiol. 2011 Mar;64(3):240-9. doi: 10.1016/j.jclinepi.2010.09.008. Epub 2010 Dec 30.

PMID:
21194888
29.

Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score.

McGorrian C, Yusuf S, Islam S, Jung H, Rangarajan S, Avezum A, Prabhakaran D, Almahmeed W, Rumboldt Z, Budaj A, Dans AL, Gerstein HC, Teo K, Anand SS; INTERHEART Investigators.

Eur Heart J. 2011 Mar;32(5):581-9. doi: 10.1093/eurheartj/ehq448. Epub 2010 Dec 22.

PMID:
21177699
30.

Appraising a tool for guideline appraisal (the AGREE II instrument).

Dans AL, Dans LF.

J Clin Epidemiol. 2010 Dec;63(12):1281-2. doi: 10.1016/j.jclinepi.2010.06.005. Epub 2010 Jul 6. No abstract available.

PMID:
20605571
31.

Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.

O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, Rangarajan S, Islam S, Pais P, McQueen MJ, Mondo C, Damasceno A, Lopez-Jaramillo P, Hankey GJ, Dans AL, Yusoff K, Truelsen T, Diener HC, Sacco RL, Ryglewicz D, Czlonkowska A, Weimar C, Wang X, Yusuf S; INTERSTROKE investigators.

Lancet. 2010 Jul 10;376(9735):112-23. doi: 10.1016/S0140-6736(10)60834-3. Epub 2010 Jun 17.

PMID:
20561675
32.

How to teach evidence-based medicine to teachers: reflections from a workshop experience.

Murad MH, Montori VM, Kunz R, Letelier LM, Keitz SA, Dans AL, Silva SA, Guyatt GH.

J Eval Clin Pract. 2009 Dec;15(6):1205-7. doi: 10.1111/j.1365-2753.2009.01344.x.

PMID:
20367728
33.

Vitamin B for treating peripheral neuropathy.

Ang CD, Alviar MJ, Dans AL, Bautista-Velez GG, Villaruz-Sulit MV, Tan JJ, Co HU, Bautista MR, Roxas AA.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD004573. doi: 10.1002/14651858.CD004573.pub3. Review.

PMID:
18646107
34.

Dechallenge and rechallenge method showed different incidences of cough among four ACE-Is.

Tumanan-Mendoza BA, Dans AL, Villacin LL, Mendoza VL, Rellama-Black S, Bartolome M, Ragual J, Flor B, Valdez J.

J Clin Epidemiol. 2007 Jun;60(6):547-53. Epub 2006 Oct 25.

PMID:
17493508
35.

Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat.

Barratt A, Wyer PC, Hatala R, McGinn T, Dans AL, Keitz S, Moyer V, For GG; Evidence-Based Medicine Teaching Tips Working Group.

CMAJ. 2004 Aug 17;171(4):353-8. Review. No abstract available.

36.

Digitalis for treatment of congestive heart failure in patients in sinus rhythm.

Hood WB Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ.

Cochrane Database Syst Rev. 2004;(2):CD002901. Review. Update in: Cochrane Database Syst Rev. 2014;4:CD002901.

PMID:
15106182
37.

Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysis.

Hood WB Jr, Dans AL, Guyatt GH, Jaeschke R, McMurray JJ.

J Card Fail. 2004 Apr;10(2):155-64. Review.

PMID:
15101028
38.

The need and means for evidence-based medicine in developing countries.

Dans AL, Dans LF.

ACP J Club. 2000 Jul-Aug;133(1):A11-2. No abstract available.

PMID:
10906850
39.

Applying the results of trials and systematic reviews to individual patients.

Glasziou P, Guyatt GH, Dans AL, Dans LF, Straus S, Sackett DL.

ACP J Club. 1998 Nov-Dec;129(3):A15-6.

PMID:
9825009
40.
41.

Supplemental Content

Support Center